Communiqués Nascent Biotech, Inc.

Actions

NBIO

US63108Q1013

Marché Fermé - OTC Markets Autres places de cotation 21:32:47 12/06/2024			Varia. 5j.	Varia. 1 janv.
0,0852 ^USD	-0,29%		-11,97%	-50,67%

16/04	Nascent Biotech, Inc. se prépare à la recherche pivotale de phase II avec un nouveau cycle de fabrication	CI
19/03	Nascent Biotech Inc. et HypoSpray Pharma annoncent une collaboration pour développer un mécanisme d'administration alternatif pour les patients qui peuvent bénéficier du Pritumumab	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run	17/04	AQ
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is significantly under Valued	10/01	AQ
Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk	20/12	AQ
Nascent Biotech : Termination of Material Agreement - Form 8-K	30/05/23	PU
NASCENT BIOTECH INC. : Other Events, Financial Statements and Exhibits (form 8-K)	09/05/23	AQ
NASCENT BIOTECH INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERTIONS (form 10-Q)	14/02/23	AQ
NASCENT BIOTECH INC. : Other Events, Financial Statements and Exhibits (form 8-K)	26/01/23	AQ
Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial	11/01/23	AQ
NASCENT BIOTECH INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERTIONS (form 10-Q)	10/11/22	AQ
Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394	02/11/22	AQ
NASCENT BIOTECH INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	28/09/22	AQ
NASCENT BIOTECH INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	20/09/22	AQ
NASCENT BIOTECH INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	09/09/22	AQ
NASCENT BIOTECH INC. Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K/A)	09/09/22	AQ
NASCENT BIOTECH INC. Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K/A)	06/09/22	AQ
NASCENT BIOTECH INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	02/09/22	AQ
NASCENT BIOTECH INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERTIONS (form 10-Q)	09/08/22	AQ
Nascent Biotech : Receives Notice of Allowance from USPTO for Issuance of Additional Patent	19/07/22	PU
NASCENT BIOTECH INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION (form 10-K)	15/06/22	AQ
NASCENT BIOTECH INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERTIONS (form 10-Q)	14/02/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Nascent Biotech, Inc.

Actions

NBIO

US63108Q1013

Communiqués

Filtres